Jiangsu, China

Shanshan Ning

USPTO Granted Patents = 4 


Average Co-Inventor Count = 10.5

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2019-2022

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Shanshan Ning: Innovator in Biopharmaceuticals

Introduction

Shanshan Ning is a prominent inventor based in Jiangsu, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative antibody therapies. With a total of 4 patents to his name, Ning is recognized for his groundbreaking work in protein complexes and monoclonal antibodies.

Latest Patents

Ning's latest patents include the "IL-10 EGFR antibody fusion protein and uses thereof." This patent provides insights into proteinaceous complexes, pharmaceutical compositions, and methods for producing these complexes. Another notable patent is for a "fully human antibody against human CD 137." This invention discloses a fully human monoclonal antibody that specifically binds to CD137, along with its CDR/variable region sequence and encoding nucleic acid sequence. The patent also outlines methods for treating diseases using this antibody.

Career Highlights

Shanshan Ning is currently associated with Dingfu Biotarget Co., Ltd., where he continues to advance his research in biopharmaceuticals. His work has garnered attention for its potential applications in treating various diseases, showcasing his commitment to innovation in the medical field.

Collaborations

Ning collaborates with notable colleagues, including Ting Xu and Yan Luan, who contribute to his research endeavors. Their combined expertise enhances the development of new therapeutic solutions.

Conclusion

Shanshan Ning's contributions to the field of biopharmaceuticals through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in antibody therapies, making a significant impact on medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…